Group B Streptococcus (GBS) is a leading cause of neonatal infection (including pneumonia, sepsis and meningitis) in Europe, and increasingly recognised as a significant cause of neonatal infection in sub-Saharan Africa. The PREPARE consortium aims to define the burden of neonatal, infant and maternal GBS in a sub-Saharan Africa population and to accelerate the development of a new GBS vaccine by conducting two phase II trials using two promising vaccine candidates: the GBS6 vaccine candidate (a trial in Uganda) and the GBS-NN/NN2 vaccine candidate (trials in Uganda and South Africa). The trial that uses the MinervaX GBS-NN/NN2 vaccine candidate aims to evaluate the safety and reactogenicity of the vaccine candidate in pregnant women. Both trial sites in South Africa and Uganda have recently completed recruitment.